Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influvac influenza vaccination responses in rituximab-treated rheumatoid arthritis
NL-OMON30994Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of influenza vaccine, rituximab and methotrexate in influenza (5 arms), sponsored by University Medical Center Groningen. Primary endpoints: Humoral immunity to vaccine antigens, Cellular immunity by ELISPOT and 2 more. Started Sep 2007; status: active, not recruiting.
02
Drugs
influenza vaccinerituximabmethotrexate
03
Conditions
influenza
Beyond the preview
Go deeper on NL-OMON30994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30994.